Truscreen Group

Truscreen Group FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Truscreen Group (TRU.NZ) as of Oct 27, 2026 is 102.04 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 99.16 % — a change of 2.91% (higher).

FCF Conversion

102.04 %

YoY

2.91%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Truscreen Group is 2025 102.04 % . FCF Conversion Rate (FCF/EBITDA) of Truscreen Group was 2024 99.16 % . It decreases by 2.91% higher compared to the previous year.

The Truscreen Group FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
76.91 NZD
Jan 1, 2018
89.53 NZD
Jan 1, 2019
91.36 NZD
Jan 1, 2020
31.45 NZD
Jan 1, 2021
65.52 NZD
Jan 1, 2022
32.11 NZD
Jan 1, 2024
99.16 NZD
Jan 1, 2025
102.04 NZD
The Truscreen Group FCF Conversion history
YEARFCF ConversionYoY
102.04 %+2.91%
99.16 %+208.80%
32.11 %-50.99%
65.52 %+108.33%
31.45 %-65.57%
91.36 %+2.04%
89.53 %+16.41%
76.91 %-63.61%
211.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Truscreen Group Stock analysis

What does Truscreen Group do? TruScreen Group Ltd develops and sells cancer detection devices and systems, focusing on cervical cancer screening. The company's AI-enabled device uses opto-electrical technology to detect precancerous and cancerous cervical changes in real-time through optical and electrical measurements of cervical tissue. The TruScreen device includes a Disposable Single Use Sensor (SUS), a Handheld Device (HHD), and an Intelligent Cradle (IC), working together to resolve issues with cytology such as failed samples, poor patient follow-up, and patient discomfort. The company also addresses challenges with HPV testing by providing an alternative solution that avoids the need for laboratory infrastructure. The primary buyers of TruScreen's products are healthcare providers and clinics specializing in women's health, particularly those seeking efficient, real-time cervical screening solutions. The technology targets segments where traditional cytology and HPV testing face limitations, such as in resource-constrained settings or where patient adherence to follow-up is low. By offering a device that eliminates the need for supporting laboratory infrastructure, TruScreen appeals to providers looking to streamline cervical cancer screening processes. TruScreen's products are designed to replace or complement existing cervical screening methods, directly addressing the shortcomings of cytology and HPV testing. The company's focus on real-time detection and ease of use positions it as a solution for healthcare systems aiming to improve early cancer detection rates while reducing patient discomfort and logistical challenges associated with current screening practices. Truscreen Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Truscreen Group stock

FCF Conversion Rate (FCF/EBITDA) of Truscreen Group is 102.04 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Truscreen Group changed from 99.16 % to 102.04 %, representing a 2.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Truscreen Group since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Truscreen Group with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Truscreen Group

All Key Metrics — Truscreen Group